arrow
H

Hani Hassoun

Memorial Sloan Kettering Cancer Center
H指数:47
被引数:9,010

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Dynamic risk stratification in smoldering multiple myeloma: Integrating evolving biomarkers with the 2/20/20 Model

动态风险分层在冒烟性多发性骨髓瘤中的应用:整合演变中的生物标志物与2/20/20模型

2026-09-240
OAAI
Stem cell autograft minimal residual disease negativity and survival outcomes for multiple myeloma autotransplant

自体干细胞移植后微小残留病阴性及多发性骨髓瘤自体移植的生存结局

2026-09-220
OAAI
Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma

粒细胞集落刺激因子对双特异性抗体启动期间细胞因子释放综合征的影响:在复发/难治性多发性骨髓瘤中的作用

2026-08-070
OAAI
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma

在多发性骨髓瘤患者中,强效CD4+ CAR T细胞扩增与非ICANS神经毒性的发生相关(cilta-cel治疗)

2026-07-290
PRE
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

功能性高风险疾病与多发性骨髓瘤晚期CAR T细胞疗法后的不良预后相关

2026-04-120
OAAI
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

双特异性抗体治疗复发/难治性多发性骨髓瘤期间巨细胞病毒再激活

2025-11-010
OAAI
Correction: Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

更正:达鲁珠单抗耐药性对复发难治性多发性骨髓瘤接受CAR T细胞治疗后临床结局的影响

2025-10-130
OA
Impact of daratumumab refractoriness on clinical outcomes following CAR T-cell therapy for relapsed refractory multiple myeloma

daratumumab难治性对复发性难治性多发性骨髓瘤CAR T细胞治疗后临床结局的影响

2025-08-140
OAAI
Outcomes in frail patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma

老年体弱患者接受BCMA靶向双特异性抗体治疗复发/难治性多发性骨髓瘤的结局

2025-05-060
OA
Restarting teclistamab and talquetamab after prolonged dose delay may not require re–step-up dosing

在长期剂量延迟后重新开始teclistamab和talquetamab治疗,可能不需要重新进行剂量递增。

2025-03-100
OA
Infectious Complications during Treatment with Commercial CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma

商业化CAR T细胞疗法和双特异性抗体治疗复发/难治性多发性骨髓瘤期间的感染并发症

BLOOD
IF23.1
2024-11-050
PRE
Defining the Rates of Cytokine Release Syndrome Associated with Talquetamab Step-up Doses

定义与Talquetamab逐步增加剂量相关的细胞因子释放综合征的发生率

BLOOD
IF23.1
2024-11-050
PRE
Body Mass Index Trajectory during Triplet Induction Therapy: Clinical Implications in Newly Diagnosed Multiple Myeloma

三联诱导治疗期间体质量指数变化轨迹:新诊断多发性骨髓瘤的临床意义

BLOOD
IF23.1
2024-11-050
PRE
Frailty and Outcomes after Bispecific T-Cell Engager Therapy for Patients with Relapsed/Refractory Multiple Myeloma

老年虚弱及双特异性T细胞接合剂疗法在复发/难治性多发性骨髓瘤患者中的结局

BLOOD
IF23.1
2024-11-050
PRE
Real-World Safety and Early Efficacy of Talquetamab in Patients with Heavily-Pretreated Relapsed/Refractory Multiple Myeloma

真实世界安全性及早期疗效:Talquetamab在重度预治疗复发/难治性多发性骨髓瘤患者中的应用

BLOOD
IF23.1
2024-11-050
PRE
Evaluating serum free light chain ratio as a biomarker in multiple myeloma
2024-10-030
OAAI
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
2024-09-190
OAAI
Unscheduled health care interactions in patients with multiple myeloma receiving T-cell redirection therapies
2024-06-140
OAAI